This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Transfusion-Dependent β-Thalassemia > Efficacy > Preventing Cardiac Iron Loading (T2* >20 ms)
Print

In this section:

Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC
Preventing Cardiac Iron Loading

EXJADE Prevents Cardiac Iron Loading in Patients Without Pre-existing Cardiac Iron Loading1


Maintained Cardiac T2* for Those
Without Pre-existing Cardiac Complications
Maintained Cardiac Iron Loading

In the prevention arm (patients with normal myocardial iron) of the EPIC cardiac substudy

  • After 12 months of treatment the T2* was 32.5 ms compared with 32.0 at
    baseline, demonstrating maintenance of normal cardiac iron levels1
  • No patient with a myocardial T2* >20 ms at baseline had a value <20 ms
    at 1 year
  • A significant increase in LVEF from 67.7% at baseline to 69.6%
    (mean change 1.8%, P<.001) was observed at 12 months1

Published data have shown that EXJADE dosed at 30 to 40 mg/kg/day maintained cardiac function and significantly reduced total body iron2,3,4

  • EXJADE is approved at doses up to 40 mg/kg/day for patients not adequately controlled with doses of 30 mg/kg (eg, serum ferritin levels persistently above 2,500 µg/lL and not showing a decreasing trend over time)5
  • Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level5

Efficacy across clinical parameters1


Proven Clinical Efficacy

Resulting in a 30%
reduction in hepatic iron1

Resulting in a 20%
relative reduction in serum ferritin levels1

To learn more about the
EPIC Cardiac substudy
Click Here

LEARN MORE ABOUT
OPTIMIZING PATIENT
TREATMENT WITH
TAILORED EXJADE
DOSING

Use the Dosing Simulator

More Information
Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC

References

  1. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
  2. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-543.
  3. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade®) in β-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. Poster presented at: 51st annual American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA.
  4. Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trial. Poster presented at: 50th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA. Abstract 3873.
  5. EXJADE® summary of product characteristics. West Sussex, United Kingdom: Novartis Europharm Limited; 2011.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed